Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 25

1.

Alveolar rhabdomyosarcoma of the head and neck region in older adults: genetic characterization and a review of the literature.

Yasuda T, Perry KD, Nelson M, Bui MM, Nasir A, Goldschmidt R, Gnepp DR, Bridge JA.

Hum Pathol. 2009 Mar;40(3):341-8. doi: 10.1016/j.humpath.2008.08.006. Epub 2008 Oct 29.

2.
3.

Fusions involving paired box and fork head family transcription factors in the pediatric cancer alveolar rhabdomyosarcoma.

Barr FG.

Curr Top Microbiol Immunol. 1997;220:113-29. Review. No abstract available.

PMID:
9103678
4.

Classification of rhabdomyosarcoma and its molecular basis.

Parham DM, Barr FG.

Adv Anat Pathol. 2013 Nov;20(6):387-97. doi: 10.1097/PAP.0b013e3182a92d0d. Review.

PMID:
24113309
5.

Prognostic value of PAX3/7-FOXO1 fusion status in alveolar rhabdomyosarcoma: Systematic review and meta-analysis.

Kubo T, Shimose S, Fujimori J, Furuta T, Ochi M.

Crit Rev Oncol Hematol. 2015 Oct;96(1):46-53. doi: 10.1016/j.critrevonc.2015.04.012. Epub 2015 May 14. Review.

PMID:
26008753
6.

Molecular biology of rhabdomyosarcoma.

Gallego Melcón S, Sánchez de Toledo Codina J.

Clin Transl Oncol. 2007 Jul;9(7):415-9. Review.

PMID:
17652054
7.
8.

Alveolar rhabdomyosarcoma: is the cell of origin a mesenchymal stem cell?

Charytonowicz E, Cordon-Cardo C, Matushansky I, Ziman M.

Cancer Lett. 2009 Jul 8;279(2):126-36. doi: 10.1016/j.canlet.2008.09.039. Epub 2008 Nov 12. Review.

PMID:
19008039
9.

A call to ARMS: targeting the PAX3-FOXO1 gene in alveolar rhabdomyosarcoma.

Olanich ME, Barr FG.

Expert Opin Ther Targets. 2013 May;17(5):607-23. doi: 10.1517/14728222.2013.772136. Epub 2013 Feb 25. Review.

PMID:
23432728
10.

New genetic tactics to model alveolar rhabdomyosarcoma in the mouse.

Keller C, Capecchi MR.

Cancer Res. 2005 Sep 1;65(17):7530-2. Review.

11.

[Alveolar rhabdomyosarcoma of unknown origin mimicking acute leukemia at the initial presentation].

Yamaguchi K, Koga Y, Suminoe A, Saito Y, Matsuzaki A, Kanno S, Takimoto T, Suda M, Oda Y, Muto T, Takatsuki H, Hara T.

Rinsho Ketsueki. 2007 Apr;48(4):315-20. Review. Japanese.

PMID:
17515123
12.

The inconvenience of convenience cohorts: rhabdomyosarcoma and the PAX-FOXO1 biomarker.

Rosenberg AR, Skapek SX, Hawkins DS.

Cancer Epidemiol Biomarkers Prev. 2012 Jul;21(7):1012-8. doi: 10.1158/1055-9965.EPI-12-0207. Epub 2012 May 7. Review.

13.

Clinical aspects of alveolar rhabdomyosarcoma with translocation t(1;13)(p36;q14) and hypotetraploidy.

Gunawan B, Füzesi L, Granzen B, Keller U, Mertens R, Steinau G, Schumpelick V.

Pathol Oncol Res. 1999;5(3):211-3. Review.

14.

Uncovering metabolism in rhabdomyosarcoma.

Monti E, Fanzani A.

Cell Cycle. 2016;15(2):184-95. doi: 10.1080/15384101.2015.1071746. Review.

15.

Molecular diagnostics in the management of rhabdomyosarcoma.

Arnold MA, Barr FG.

Expert Rev Mol Diagn. 2017 Feb;17(2):189-194. doi: 10.1080/14737159.2017.1275965. Epub 2017 Jan 6. Review.

PMID:
28058850
16.

Biology and therapy of pediatric rhabdomyosarcoma.

Pappo AS, Shapiro DN, Crist WM, Maurer HM.

J Clin Oncol. 1995 Aug;13(8):2123-39. Review.

PMID:
7636557
17.

PAX3-FKHR chimeric oncoprotein: hiding itself from immune detection?

Anderson J, Himoudi N.

Cell Cycle. 2006 Mar;5(6):563-4. Epub 2006 Mar 15. Review. No abstract available.

PMID:
16481750
18.

Probing for a deeper understanding of rhabdomyosarcoma: insights from complementary model systems.

Kashi VP, Hatley ME, Galindo RL.

Nat Rev Cancer. 2015 Jul;15(7):426-39. doi: 10.1038/nrc3961. Review.

19.

What is new in the biology and treatment of pediatric rhabdomyosarcoma?

Hawkins DS, Gupta AA, Rudzinski ER.

Curr Opin Pediatr. 2014 Feb;26(1):50-6. doi: 10.1097/MOP.0000000000000041. Review.

20.

The case for primary salivary rhabdomyosarcoma.

Geltzeiler M, Li G, Abraham J, Keller C.

Front Oncol. 2015 Apr 1;5:74. doi: 10.3389/fonc.2015.00074. eCollection 2015. Review.

Supplemental Content

Support Center